Latest News about AZN
Recent news which mentions AZN
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
April 25, 2024
From Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
April 25, 2024
From Benzinga
Tickers
AZN
From InvestorPlace
From Benzinga
From InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
From Benzinga
From Benzinga
3 Blue-Chip Stocks to Buy as High Inflation Persists
April 19, 2024
From InvestorPlace
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
From Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
From Benzinga
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
From InvestorPlace
From Motley Fool
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
From Benzinga
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
From Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
From Benzinga
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
April 07, 2024
From Benzinga
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
April 05, 2024
From Benzinga
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
From Benzinga
From InvestorPlace
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
March 28, 2024
From Motley Fool
From Benzinga
From Benzinga
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
March 21, 2024
From Benzinga
From Benzinga
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
March 20, 2024
From InvestorPlace
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
From Benzinga
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?
March 19, 2024
From InvestorPlace
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.